drugset
drugset / Trial / NCT02151110

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

NCT02151110 ↗

Phase 1 Completed 59 enrolled MedImmune LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

Timeline

Start
2014-05-27
Primary completion
2016-05-09
Completion
2016-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dazodalibep Protein / enzyme biologic 3 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 10 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 30 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 100 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 300 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 1000 mg Intravenous
Subject Dazodalibep Protein / enzyme biologic 3000 mg Intravenous

Indications

No indication recorded.